Sign inJoin waitlistJoin the waitlist

Philip Philip

Neuroendocrine Oncology Director · Henry Ford Health

Credentials: · · · ·

History

Pancreatic Cancer Center · Henry Ford Health
Present
Research and Clinical Care Integration · Henry Ford Health
Present

University of Texas Health Science Center
1993–1995
University of Baghdad
1977–1980
University of Texas - MD Anderson Cancer Center, TX
1973–1977

Research

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
JAMA Oncology · 2018 · 1,507 citations
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
JAMA Oncology · 2019 · Last of 14 authors · 630 citations
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study
Journal of Clinical Oncology · 2013 · 630 citations

AS
Anthony Shields
73 papers
Bassel El-Rayes
39 papers · 1 as a fellow
MZ
Mark Zalupski
26 papers
Heinz-Josef Lenz
25 papers
John Marshall
23 papers
EO
Eileen O'Reilly
19 papers
WK
Wolfgang Korn
18 papers
RG
Richard Goldberg
16 papers
Andrew Lowy
15 papers · 5 as a resident
Mohamed Salem
15 papers
MH
Mohammed Al Hallak
14 papers
Jimmy Hwang
13 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $496K · Wayne State University
2011–2015

Clinical trials

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Principal investigator · Completed · Phase 3
Cornerstone Pharmaceuticals
2018–2022
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
Principal investigator · Completed
Philip Philip
2012–2020
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)
2008–2014
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Principal investigator · Completed · Phase 2
Barbara Ann Karmanos Cancer Institute
2004–2013